A compound selected from those of formula (I): wherein m and n, which may be identical or different, each represent an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive, p and q, which may be identical or different, each represent an integer from 0 to 2 inclusive, Alk represents an alkylene, alkenylene or alkynylene chain, X represents an oxygen atom, a sulphur atom or an --N(R)-- group wherein R represents a hydrogen atom or an alkyl group, Y, Y' and W are as defined in the description, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful for treating conditions associated with central histaminergic systems.
A compound selected from those of formula (I): 1 wherein A, B, D, X, R.sup.1, R.sup.2, m and n are as defined in the description, their diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base.
A compound selected from those of formula (1): ##STR1## wherein W represents aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each being optionally substituted, R.sub.1 represents alkyl, alkenyl, alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl, each being optionally substituted. R.sub.2 is as defined in the description, its isomers, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as anti-oxidation agents.
New N-substituted cyclic amines of formula: ##STR1## wherein: X, R.sub.1, R.sub.2 and R are as defined in the description, their optical and geometric isomers and physiologically tolerable salts thereof. The compounds of the invention are powerful PDE4 inhibitors and can be used therapeutically.
A compound of general formula (I): ##STR1## in which: R.sub.1 represents alkyl, X represents oxygen, --CHR'-- or --CR'.dbd., R' is chosen from hydrogen and alkyl, R.sub.2 represents optionally substituted alkyl as is defined in the description, cycloalkyl or polycycloalkyl as are defined in the description, R.sub.3 represents hydrogen or hydroxyl, Alk represents alkylene, and Y is as defined in the description, and medicinal products containing the same are useful as PDE IV inhibitors.